KBC Group’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-2,828
Closed -$10K 1877
2023
Q3
$10K Sell
2,828
-422
-13% -$2.34K ﹤0.01% 1915
2023
Q2
$24K Sell
3,250
-911
-22% -$8.45K ﹤0.01% 1458
2023
Q1
$43K Hold
4,161
﹤0.01% 1416
2022
Q4
$49K Hold
4,161
﹤0.01% 1394
2022
Q3
$87K Sell
4,161
-453
-10% -$12.6K ﹤0.01% 1241
2022
Q2
$143K Buy
+4,614
New +$158K ﹤0.01% 1086
2021
Q4
Sell
-471
Closed -$24K 1298
2021
Q3
$24K Sell
471
-1,215
-72% -$73.6K ﹤0.01% 1282
2021
Q2
$106K Hold
1,686
﹤0.01% 1222
2021
Q1
$156K Hold
1,686
﹤0.01% 1207
2020
Q4
$831K Hold
1,686
﹤0.01% 1167
2020
Q3
$174K Hold
1,686
﹤0.01% 1133
2020
Q2
$134K Buy
1,686
+843
+100% +$62.8K ﹤0.01% 1191
2020
Q1
$49K Sell
843
-1,768
-68% -$102K ﹤0.01% 1200
2019
Q4
$141K Hold
2,611
﹤0.01% 1322
2019
Q3
$137K Hold
2,611
﹤0.01% 1309
2019
Q2
$126K Buy
+2,611
New +$125K ﹤0.01% 1290
2015
Q1
Sell
-3,663
Closed -$100K 1367
2014
Q4
$100K Buy
+3,663
New +$87.3K ﹤0.01% 1316
2014
Q2
Sell
-2,180
Closed -$55K 1341
2014
Q1
$55K Hold
2,180
﹤0.01% 1205
2013
Q4
$50K Buy
+2,180
New +$45.5K ﹤0.01% 1223

Other funds holding EBS

KBC Group's EBS Position: Q4 2023 in Review

KBC Group sold out of Emergent Biosolutions (EBS) in Q4 2023, closing a stake of 2,828 shares — an estimated $10K sold.

KBC Group first reported a position in EBS in Q4 2013 and held it in 19 quarters. The position peaked at $831K in Q4 2020. 134 funds tracked by Wall St. Rank hold EBS as of Q4 2023.

  • KBC Group reported no remaining Emergent Biosolutions position as of Q4 2023 after selling out during the quarter.
  • KBC Group sold 2,828 Emergent Biosolutions shares in Q4 2023, an estimated $10K.
  • KBC Group first reported a position in Emergent Biosolutions in Q4 2013 and held it in 19 quarters.
  • KBC Group's Emergent Biosolutions position peaked at $831K in Q4 2020.
  • 134 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2023.

Based on KBC Group's 13F filing for Q4 2023, filed 13 Feb 2024.